Dr. Joseph Kim received his medical oncology fellowship training at National Cancer Institute, NIH, where he received training in development of clinical trials of novel cancer therapies for genitourinary cancers and other solid tumors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). Dr. Kim specializes in early phase clinical trials of novel cancer therapies and in caring for patients with prostate cancer, urinary tract and bladder cancer, penile cancer, testicular cancer, and other genitourinary malignancies. Dr. Kim research interest include DNA repair pathway, mTOR pathway, tumor hypoxia, cancer immunotherapy. Dr. Kim is currently spearheading several NCI-sponsored clinical trials of PARP inhibitor, olaparib in combination with a VEGFR tyrosine kinase inhibitor, cediranib, in prostate cancer (CTEP# 9984) and in other advanced solid tumors (CTEP #9881) as well as a mTOR inhibitor, sapanisertib (aka TAK228 or MLN0128) for advanced urinary tract cancers (CTEP #9767) as the Study Chair. He is an active member of Society of Immunotherapy of Cancer, AACR and ASCO.